ACM
PBYI icon

Aquatic Capital Management’s Puma Biotechnology PBYI Stock Holding History

Aquatic Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600
Closed -$2K – 1477
2022
Q1 		$2K Buy
+600
New +$1.55K ﹤0.01% 977

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aquatic Capital Management's PBYI Position: Q2 2022 in Review

Aquatic Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2022, closing a stake of 600 shares — an estimated $2K sold.

Aquatic Capital Management first reported a position in PBYI in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q2 2022.

  • Aquatic Capital Management reported no remaining Puma Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 600 Puma Biotechnology shares in Q2 2022, an estimated $2K.
  • Aquatic Capital Management first reported a position in Puma Biotechnology in Q1 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Puma Biotechnology position peaked at $2K in Q1 2022.
  • 88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2022.

Based on Aquatic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.